A randomized controlled trial comparing tapentadol with oxycodone in non-breastfeeding women post elective cesarean section

References

• Kuczkowski KM. Postoperative pain control in the parturient: new challenges in the new millennium. J Matern Fetal Neonatal Med 2011;24:301–4
   PubMed Web of Science ®Google Scholar
• Gadsden J, Hart S, Santos AC. Post-cesarean delivery analgesia. Anesth Analg 2005;101(5 Suppl):S62–S9
   PubMed Web of Science ®Google Scholar
• Dahl JB, Jeppesen IS, Jorgensen H, et al. Intraoperative and postoperative analgesic efficacy and adverse effects of intrathecal opioids in patients undergoing cesarean section with spinal anesthesia: a qualitative and quantitative systematic review of randomized controlled trials. Anesthesiology 1999;91:1919–27
   PubMed Web of Science ®Google Scholar
• Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med 2015;16:119–30
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kogel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 2014;28:319–29
   PubMed Web of Science ®Google Scholar
• Baron R, Likar R, Martin-Mola E, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. Pain Pract 2016;16:580–99
   PubMed Web of Science ®Google Scholar
• Daniels SE, Upmalis D, Okamoto A, et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25:765–76
   PubMed Web of Science ®Google Scholar
• Xiao JP, Li AL, Feng BM, et al. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and meta-analysis. Pain Med 2017;18:14–24
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Severtson SG, Dart RC, et al. Assessment of tapentadol API abuse liability with the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) system. J Pain 2017;19(4):439–53
   PubMed Web of Science ®Google Scholar
• Sanchez Del Aguila MJ, Schenk M, Kern KU, et al. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther 2015;37:94–113
   PubMed Web of Science ®Google Scholar
• Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10:416–27
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27:151–62
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database Syst Rev 2015;(9):CD011460
   PubMed Web of Science ®Google Scholar
• Lange B, von Zabern D, Elling C, Dubois C. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Curr Med Res Opin 2017;33:1413–22
   PubMed Web of Science ®Google Scholar
• Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31:260–71
   PubMed Web of Science ®Google Scholar
• Biondi D, Xiang J, Benson C, et al. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Pain Physician 2013;16:E237–46
   PubMed Web of Science ®Google Scholar
• Frampton JE. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 2010;70:1719–43
   PubMed Web of Science ®Google Scholar
• Lee YK, Ko JS, Rhim HY, et al. Acute postoperative pain relief with immediate-release tapentadol: randomized, double-blind, placebo-controlled study conducted in South Korea. Curr Med Res Opin 2014;30:2561–70
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Chang S, Mehta V. Tapentadol – the evidence so far. Anaesthesia 2015;70:518–22
   PubMed Web of Science ®Google Scholar
• Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997;33:328–43
   PubMed Web of Science ®Google Scholar
• Li Z, Pergolizzi JV, Huttner RP, et al. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs. J Clin Pharm Ther 2015;40:615-19
   PubMed Web of Science ®Google Scholar
• Marcus H, Gerbershagen HJ, Peelen LM, et al. Quality of pain treatment after caesarean section: results of a multicentre cohort study. Eur J Pain 2015;19:929–39
   PubMed Web of Science ®Google Scholar
• Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003;97:534–40, table of contents
   PubMed Web of Science ®Google Scholar
• Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med 2010;11:1859–71
   PubMed Web of Science ®Google Scholar
• Nikolajsen L, Sorensen HC, Jensen TS, Kehlet H. Chronic pain following Caesarean section. Acta Anaesthesiol Scand 2004;48:111-16
   PubMed Web of Science ®Google Scholar
• Christoph T, De Vry J, Schiene K, et al. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol 2011;666:72–9
   PubMed Web of Science ®Google Scholar
• Elling C, Galic M, Steigerwald I. Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy. Lancet Neurol 2015;14:684–5
   PubMed Web of Science ®Google Scholar
• Buhagiar LM, Cassar OA, Brincat MP, et al. Pre-operative pain sensitivity: a prediction of post-operative outcome in the obstetric population. J Anaesthesiol Clin Pharmacol 2013;29:465–71
   PubMedGoogle Scholar
• Buhagiar L, Cassar OA, Brincat MP, et al. Predictors of post-caesarean section pain and analgesic consumption. J Anaesthesiol Clin Pharmacol 2011;27:185–91
   PubMedGoogle Scholar
• Chen YJ, Chiang CC, Huang PJ, et al. Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan. Curr Med Res Opin 2015;31:2001–9
   PubMed Web of Science ®Google Scholar
• Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287–94
   PubMed Web of Science ®Google Scholar
• Niklasson B, Arnelo C, Ohman SG, et al. Oral oxycodone for pain after caesarean section: a randomized comparison with nurse-administered IV morphine in a pragmatic study. Scand J Pain 2017;7:17–24
   Web of Science ®Google Scholar
• Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain 2013;14:1227–41
   PubMed Web of Science ®Google Scholar
• Gornall BF, Myles PS, Smith CL, et al. Measurement of quality of recovery using the QoR-40: a quantitative systematic review. Br J Anaesth 2013;111:161–9
   PubMed Web of Science ®Google Scholar
• Imdad A, Yakoob MY, Bhutta ZA. Effect of breastfeeding promotion interventions on breastfeeding rates, with special focus on developing countries. BMC Publ Health 2011;11(Suppl 3):S24
   PubMedGoogle Scholar